GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Our focus is not only to discover; our aim is to significantly improve patient outcomes. This bold vision, together with our commitment to groundbreaking research, makes GIO Therapeutics a leader in the field. Our strategic approach to drug development positions us as a compelling opportunity in a rapidly evolving field.
GIO Therapeutics is a proud venture of Cumulus Oncology.
At GIO Therapeutics, our strength lies in our team. Each member brings a unique set of skills and experiences, all united by a shared passion for oncology drug discovery and a history of building and creating successful companies.
Clare Doris has built a distinguished career founding and managing companies within the oncology sector. Her strategic vision and leadership have been pivotal in the growth of numerous successful ventures. As the current COO of Cumulus, Clare's ambitious expansion plans are backed by her vast experience and sharp business acumen. Her guidance will be indispensable to the successful launch and growth of GIO Therapeutics.
Tilly Bingham brings a rich tapestry of experience from the pharmaceutical and biotech worlds. With a solid foundation in chemistry, her expertise is vast, covering areas from company establishment to intricate project management and innovative product development. Tilly's proven ability to craft strategic roadmaps and metamorphose fresh ideas into impactful products will be crucial for GIO Therapeutics.
At GIO Therapeutics, we believe in the power of collaboration to drive innovation and achieve groundbreaking results in oncology. Our commitment to pioneering the future of oncology is strengthened when we join forces with like-minded professionals and organisations.
If you possess an asset, target, or unique expertise that aligns with our mission, we invite you to connect with us. Together, we can explore the potential of our combined strengths.
For investors keen on being part of our journey and eager to learn more about our endeavours, we welcome the opportunity to discuss our vision, progress, and the promising future ahead.
